Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients
Completed
Conditions studied: Breast Cancer, Breast Neoplasm
In brief
This research study is designed to work in cooperation with another study being conducted by the National Cancer Institute. The National Cancer Institute (NCI) is studying the effects of a drug called raloxifene on premenopausal women believed to have a high risk of developing breast cancer (98-C-0123). In this study, researchers are interested in learning about the effects of raloxifene on the uterus and ovaries of the women participating in the NCI study. To do this researchers plan to conduct ultrasounds on the patients enrolled in the NCI study. In addition researchers plan to take samples of the lining of the uterus in these patients (endometrial biopsy) if found to be necessary. The purpose of this study is to determine the reproductive effects of raloxifene on women who have normal functioning ovaries by taking ultrasounds of the ovaries and lining of the uterus (endometrium).
Key facts
- Study ID
- NCT00001837
- Run by
- National Institutes of Health Clinical Center (CC)
- People needed
- 60
- Starts
- 1998-11-01
- Expected to finish
- 2005-10-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- National Institutes of Health Clinical Center (CC) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.